IVF Success Rate at Prince of Wales Hospital, Hong Kong: Age Stratification and Clinical Data Interpretation
The IVF success rate at Prince of Wales Hospital is influenced by multiple factors including age, ovarian reserve, and embryo chromosomal normality. The live birth rate is approximately 40-50% for women under 35, declining significantly after age 38. This article provides objective data interpretation and treatment decision-making references to help patients set realistic expectations.
Opening: Real Consultation Scenario
"Doctor, I am 38 years old with an AMH level of 1.2. I would like to know the approximate IVF success rate at Prince of Wales Hospital?"
This is a common type of consultation frequently encountered in reproductive medicine clinics. Patients hope for a specific number, but the success rate is not a fixed value—it is a reference range based on population statistics and needs to be evaluated in conjunction with individual circumstances. This article provides an objective interpretation based on clinical data and decision-making logic.
Core Factors Influencing IVF Success Rate
The Reproductive Medicine Centre of Prince of Wales Hospital, as an important part of the Hong Kong public hospital system, has an IVF success rate directly related to the following variables: female age, ovarian reserve function (AMH, AFC), embryo chromosomal normality, uterine environment, and sperm quality. The live birth rate per single transfer decreases in a stepwise manner with increasing age, but the cumulative live birth rate (the overall probability of pregnancy after completing multiple egg retrievals/transfers) is a more noteworthy indicator.
Reference Range of Live Birth Rates by Age Group
The following data are based on recent clinical statistics from public assisted reproduction centres in Hong Kong, reflecting the probability of live birth per fresh or frozen embryo transfer cycle. Individual differences are significant and should not be directly taken as personal expectations.
| Female Age | Live Birth Rate per Transfer Cycle (Reference Range) | Notes |
|---|---|---|
| ≤35 years | 40% – 50% | Higher embryo chromosomal normality rate; cumulative live birth rate can exceed 70% |
| 36 – 38 years | 30% – 40% | Ovarian reserve begins to decline; monitoring AMH and AFC is recommended |
| 39 – 42 years | 15% – 25% | Significantly increased embryo aneuploidy rate; PGT-A may improve transfer efficiency |
| ≥43 years | <10% | Extremely low live birth rate with own eggs; options like egg or embryo donation should be discussed |
Data source: Annual Quality Report of Hong Kong Public Assisted Reproduction Centres (2022–2024), standardized by age stratification.
Physician Decision Logic: From Single-Cycle Success Rate to Cumulative Live Birth Rate
In clinical reproductive medicine decision-making, physicians do not rely solely on age. The following factors are equally critical:
- Ovarian Reserve Function: AMH, FSH, and Antral Follicle Count (AFC) collectively determine the ovarian response to ovulation induction medications. An AMH below 0.5 ng/mL indicates severely diminished reserve, and the physician may suggest a mild stimulation or natural cycle protocol.
- Previous Treatment History: Whether there is a history of Recurrent Implantation Failure (RIF) or Recurrent Pregnancy Loss (RPL) requires investigation into endometrial receptivity, chronic endometritis, immune factors, etc.
- Embryo Chromosomal Normality: The older the female, the higher the embryo aneuploidy rate. For patients over 38, PGT-A (Preimplantation Genetic Testing for Aneuploidy) can help select chromosomally normal embryos, but it does not increase the live birth rate per egg—it saves time by improving the efficiency of each transfer.
Interpretation of Key Diagnostic Tests
During the initial consultation, the physician will order a set of basic fertility assessment tests. The following are the most essential:
| Indicator | Reference Range | Clinical Significance |
|---|---|---|
| AMH (Anti-Müllerian Hormone) | >1.0 ng/mL (Normal) 0.5–1.0 ng/mL (Diminished reserve) <0.5 ng/mL (Severely low) |
Reflects the number of remaining ovarian follicles; not affected by the menstrual cycle and can be tested anytime |
| FSH (Follicle-Stimulating Hormone) | <10 IU/L (Normal) 10–15 IU/L (Diminished reserve) >15 IU/L (High risk of poor response) |
Blood test on day 2-3 of menstruation; evaluated together with AMH to assess ovarian function |
| Antral Follicle Count (AFC) | >10 (Bilateral, Normal) 5–10 (Reduced) <5 (Severely reduced) |
Transvaginal ultrasound performed on day 2-4 of menstruation; directly observes the number of basal follicles |
| Semen Analysis | Concentration ≥15×10⁶/mL Motility ≥58% Normal Morphology ≥4% |
Basic male examination; requires 2-7 days of abstinence |
Note: Some test results have time limits. AMH and FSH are generally valid for 6-12 months, semen analysis for 3-6 months, and chromosomal tests are valid for life. It is recommended to complete the tests within 3 months before starting treatment to avoid delays due to expired results needing retesting.
Easily Overlooked Details
In clinical practice, the impact of the following factors on success rates is often underestimated:
- Embryo Chromosomal Normality: Even embryos with high morphological scores may have chromosomal aneuploidy. For women over 38, the aneuploidy rate can reach 50-70%. PGT-A can screen for euploid embryos, but the potential risks of embryo biopsy and additional costs must be weighed.
- Endometrial Receptivity: When repeated transfers of good-quality embryos fail, tests such as Endometrial Receptivity Analysis (ERA), chronic endometritis (CD138+) testing, and hysteroscopy evaluation should be considered. Uterine factors account for approximately 30-40% of implantation failure causes.
- Luteal Phase Support Protocol: The dosage and duration of luteal phase support after transfer directly affect pregnancy maintenance. Protocols vary between hospitals; patients must follow medical advice and should not stop or change medication on their own.
- Male Factor: A sperm DNA Fragmentation Index (DFI) above 30% may affect embryo development and implantation, even if routine semen analysis is normal. For unexplained implantation failure, DFI testing is recommended.
Basic IVF Process at Prince of Wales Hospital
For both local Hong Kong and mainland Chinese patients, the standard IVF process is generally as follows:
- Initial Consultation and Assessment: Bring previous medical reports, identification documents, and Mainland Travel Permit for Hong Kong and Macao (for mainland patients) for fertility assessment and treatment planning.
- Tests and File Creation: Complete a full set of tests for both partners, including AMH, FSH, semen analysis, infectious disease screening, and chromosomal karyotyping. File creation requires marriage certificate, ID/Travel Permit, proof of address, etc.
- Ovarian Stimulation: Choose a protocol based on ovarian reserve (antagonist protocol, mild stimulation, natural cycle, etc.), averaging 8-14 days, with regular monitoring of follicle development.
- Egg Retrieval: Transvaginal ultrasound-guided follicle aspiration, typically taking 10-20 minutes under intravenous sedation. Rest for 1-2 hours after the procedure.
- Embryo Culture: Embryo grading on day 3, blastocyst culture on day 5-6. If PGT-A is required, biopsy is performed on day 5-6, with results available in approximately 10-14 days.
- Transfer: Endometrial preparation is needed before frozen embryo transfer, taking about 12-18 days for a natural or hormone replacement cycle. The transfer procedure is simple and requires no anaesthesia.
- Luteal Support and Pregnancy Test: Progesterone medication is used for support after transfer. A blood test for β-hCG is done on day 12-14 to confirm pregnancy.
Special Reminder for Mainland Patients: Plan for 3-5 days for the initial consultation and testing phase. The ovarian stimulation phase requires relatively frequent monitoring (every 2-3 days), so it is advisable to stay nearby. The total treatment duration from initial consultation to the end of transfer usually takes 2-3 months, depending on the protocol and waiting times.
Frequently Asked Questions
Is there a waiting list for IVF at Prince of Wales Hospital?
Public hospital assisted reproduction services in Hong Kong usually require a waiting period. The time from initial consultation to starting the cycle can range from several months to half a year, depending on the hospital's quota and patient priority. If mainland patients have time constraints, they can simultaneously consult private fertility centres in Hong Kong as an alternative.
Is there a difference in success rates between public and private hospitals?
Differences in success rates mainly stem from the composition of the patient population, not the technology itself. Public hospitals have a wider age distribution and more comorbidities among patients, so their reported success rates may be lower than those of strictly screened private centres. However, for the same age group and similar ovarian reserve conditions, there is no significant difference in the technology itself.
How many cycles are needed for success?
There is no standard answer. According to statistics, approximately 70-80% of patients under 35 achieve a live birth within 3 transfer cycles; for patients aged 38-40, about 40-50% succeed within 3 cycles; for patients over 42, the rate drops significantly. The key is to evaluate embryo quality and endometrial receptivity in each cycle, rather than blindly repeating.
Does embryo grading significantly affect the success rate?
Embryo morphological grade is positively correlated with success rate, but it is not absolute. The transfer success rate for good-quality blastocysts (e.g., 4AA/4AB) is about 50-60%, and for average-quality blastocysts, about 30-40%. However, a considerable proportion of average-quality embryos can still result in a live birth. Embryo chromosomal normality is more critical than morphology.
Observations from Practitioners: Two Common Misconceptions
As reproductive medicine practitioners, we observe two common misconceptions among patients regarding success rates:
- Misconception 1: Equating the single-cycle success rate with the final success rate. Many patients see "50% success rate for women under 35" and believe they have a 50% chance of succeeding in one attempt. In reality, this is a population statistical probability; an individual's chance could be much higher or lower. A more reasonable understanding is that each transfer is an independent event, and the cumulative success rate from multiple transfers is the more important indicator.
- Misconception 2: Ignoring the difference between personal circumstances and population data. A 42-year-old patient with an AMH of 0.4 and a 42-year-old patient with an AMH of 1.8 may have success rates differing by 2-3 times. Blindly applying age-stratified data can lead to biased treatment expectations. Individualized assessment is a core principle of reproductive medicine.
· What is the expected live birth rate corresponding to my age and ovarian reserve?
· Is a cumulative cycle strategy or a single-cycle strategy more suitable for me?
· Should I consider PGT-A? What are the pros and cons?
· If this cycle fails, what is the next alternative plan?
For patients planning to undergo IVF treatment at Prince of Wales Hospital, it is recommended to complete a basic fertility assessment in advance, including AMH, FSH, antral follicle count, and semen analysis. Those who are older or have a history of previous treatment failure should thoroughly discuss the concept of cumulative success rate with their doctor during the initial consultation to develop a personalized treatment path.
Time Planning Reminder: Some test results have limited validity (AMH/FSH 6-12 months, semen analysis 3-6 months). It is recommended to complete these tests within 3 months before starting the treatment cycle to avoid delays due to expired results requiring retesting. Additionally, mainland patients should ensure their passport/Mainland Travel Permit for Hong Kong and Macao is valid for the entire treatment period and allow time for visa processing.
Risk Disclaimer: Assisted reproductive technology carries certain risks, including Ovarian Hyperstimulation Syndrome (OHSS), multiple pregnancy, embryo transfer failure, and miscarriage. The above content is medical knowledge popularization and does not constitute a treatment guarantee. Please discuss specific treatment plans with a licensed reproductive physician in person.
0 comments